Société
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
We are pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health.
Villigen, Aargau, Suisse
Envoyer un message
Français
Anglais
Français
Anglais
InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). It has developed a unique drug discovery platform to reduce the time and costs for discovery and development of new drugs for a wide array of human diseases. InterAx technology combines in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new...
InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). It has developed a unique drug discovery platform to reduce the time and costs for discovery and development of new drugs for a wide array of human diseases. InterAx technology combines in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new effective treatments and de-risk clinical trials.
Partnerships with leading pharmaceutical companies, Boehringer Ingelheim and Lundbeck, and South Korean biotech company, GPCR Therapeutics, allowed us to validate the technology platform. InterAx is currently applying its technology to an in-house drug discovery program in the field of oncology and has discovered a new molecular entity targeting solid tumours in several cancer subtypes with high unmet needs.